SCHEMBL7511054

SCHEMBL7511054

O=C1NC(=O)C(=Cc2ccc(-c3nc4cc(Cl)c(Cl)cc4[nH]3)s2)S1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.46
PIK3CA P42336 2/20 0.46
PIK3CG P48736 2/20 0.46
PRF1 P14222 1/20 0.44
GSK3B P49841 4/20 0.43
PIM1 P11309 2/20 0.41
PIM2 Q9P1W9 2/20 0.41
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
HTT P42858 1/20 0.39
HPGD P15428 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
RHEB Q15382 1/20 0.39
INSR P06213 1/20 0.39
CISD1 Q9NZ45 2/20 0.39
PIK3CD O00329 1/20 0.39
CSNK2A2 P19784 1/20 0.39
MAOB P27338 1/20 0.39
PIK3CB P42338 1/20 0.39
MTOR P42345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7511049 1.00 IGF1R (0.46) IGF1RPIK3CAPIK3CGPRF1GSK3B
SCHEMBL7516823 0.82 IGF1R (0.56) IGF1RPIK3CAPIK3CGGSK3BPIM1
SCHEMBL7516825 0.82 IGF1R (0.56) IGF1RPIK3CAPIK3CGGSK3BPIM1
SCHEMBL7514180 0.81 IGF1R (0.42) IGF1RGSK3BPIM1PIM2HPGD
SCHEMBL7512576 0.81 IGF1R (0.42) IGF1RGSK3BPIM1PIM2NPC1
SCHEMBL7514183 0.81 IGF1R (0.42) IGF1RGSK3BPIM1PIM2HPGD
SCHEMBL7512568 0.81 IGF1R (0.42) IGF1RGSK3BPIM1PIM2NPC1
SCHEMBL7514959 0.79 RHEB (0.48) NPC1RAB9AHTTHPGDRHEB
SCHEMBL7521699 0.78 IGF1R (0.44) IGF1RPIK3CAPIK3CGGSK3BPIM1
SCHEMBL7521696 0.78 IGF1R (0.44) IGF1RPIK3CAPIK3CGGSK3BPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed
EP-0937042-A1 HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1999-08-25 EP disclosed
WO-1998017643-A1 HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1998-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 IGF1R 1097/4885PIK3CA 1572/4885PIK3CG 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.